ARENTFOX SCHIFF LLP for CHILDREN'S HEALTHCARE OF ATLANTA
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Section 340B Drug Pricing Program, including H.R. 9599 (SECURE 340B Act), all provisions S. 5244 (SUSTAIN 340B Act), all provisions Sickle cell disease research funding generally Drug pricing reforms generally Mental and behavioral health legislation generally H.R. 2107 (Children's Hospital GME Support Reauthorization Act of 2025), all provisions Site neutral payments to providers generally Federal telehealth policy generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| KELSEY GRISWOLD-BERGER | — |
| DAN RENBERG | — |
| OLIVER SPURGEON III | — |
| BLAKE THELANDER | — |
Budget/Appropriations BUD
Autism research programs and autism intervention programs generally, including Medicaid coverage of detection methodologies Department of Health and Human Services programs regarding autism and sickle cell disease research Implementation of H.R. 1 (One Big Beautiful Bill Act), Sections 71115, 71116, regarding Medicaid funding H.R. 9260 (Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027) Title II, regarding Children's Hospital Graduate Medical Education (CHGME) program, National Institutes of Health funding, sickle cell disease research, and other programs related to pediatric healthcare
| Lobbyist | Covered position, as disclosed |
|---|---|
| KELSEY GRISWOLD-BERGER | — |
| DAN RENBERG | — |
| OLIVER SPURGEON III | — |
| BLAKE THELANDER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.